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The existence of fi-adrenergic receptors was demonstrated on whole A43 1 cells as well as A43 1 membrane 
preparations by means of binding assays using the hydrophobic I-[‘Hldihydroalprenolol and the 
hydrophilic antagonist [3H]CGP-12,177 as&adrenergic ligands. Binding was stereospecific. The receptors, 
as shown by competition studies, proved to be of theflz-subtype and appeared functional in the stimulation 
of adenylate cyclase. The number of receptors per cell and the yield of receptor sites/mg membrane protein 
render the A431 cell a useful tool for the study of human ,&adrenergic receptors. 
&Adrenergic receptor Human epidermoid carcinoma cell I-Dihydroalprenolol CGP-12,177 
1. INTRODUCTION these cells an ideal tool for topological and struc- 
tural studies. 
Molecular studies of catecholamine-stimulated 
,8-adrenergic system have mainly been performed 
on proteins obtained from avian [l] and amphi- 
bian [2] erythrocytes. However, the properties of 
these receptor-cyclase complexes are not 
necessarily similar to those of mammalian recep- 
tors [3]. Several investigators [4-61 have thus turn- 
ed their attention to tissues and cells from murine 
and human origin. The paucity of receptor density 
and the difficulty in growing cells in sufficiently 
large amounts have often hampered molecular 
analysis of the receptors. We here describe the ex- 
istence of large numbers of functionally active ,& 
receptors on the A431 human epidermoid cell line, 
which is well known as possessing excellent growth 
properties and having an unusually high number of 
epidermal growth factor receptors [7]. The binding 
characteristics of the adrenergic receptor and their 
interaction with the adenylate cyclase system make 
Abbre’viations: CGP-12,177, 4-[3-(t-butylamino)-2-hy- 
droxypropoxylbenzimidazol-Zone; EGF, epidermal 
growth factor; Gpp(NH)p, 5’-guanylyl imidodiphos- 
phate 
2. MATERIALS AND METHODS 
2.1. Drugs 
[3H]Dihydroalprenolol (49 Ci/mmol) was pur- 
chased from New England Nuclear and 
[‘H]CGP-12,177 (34 CVmmol) from Amersham. 
dl-Alprenolol was a gift from Ciba-Geigy and d- 
and I-propranolol from ICI. l- and d-Isopro- 
terenol, l-adrenaline and I-noradrenaline were ac- 
quired from Sigma. 
2.2. Saturation binding curve of dihydro- 
alprenolol and CGP-12,177 on intact A431 
cells 
Cells grown in Costar plates (35 mm diameter 
wells) until confluence (8 x lo5 cells/well) were 
washed 5 times with 2 ml of Hank’s balanced salt 
solution, buffered with 10 mM Hepes at pH 7.4 
and supplemented with O.lVo bovine serum 
albumin and 1 mM ascorbic acid. Increasing con- 
centrations of radioligand in 1 ml of the same buf- 
fer were added per well. 
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Dihydroalprenolol binding was performed by in- 
cubation at 25°C for 10 min. Cells were then wash- 
ed 5 times with cold buffer and lysed in 3 x 0.5 ml 
of 0.01 M Tris buffer (containing SDS to 0.5% 
and EDTA to 1 mM). The lysate was transferred 
to scintillation vials. 
Binding of CGP-12,177 was performed as in [8]. 
Cells were incubated for 60 min at 30°C with the 
radioligand. The reaction was stopped by addition 
of 2 ml cold hypotonic buffer [lo mM phosphate 
buffer (pH 7.4), 1 mM MgS04] and the cells wash- 
ed 5 times in the same buffer. Lysis was done with 
2% SDS and lysates transferred to scintillation 
vials. 
Non-specific binding for both radioligands was 
assessed by carrying out incubation in the presence 
of 100 PM 1-isoproterenol. 
2.3. Saturation binding curve of dihydro- 
alprenolol and CGP-12,177 on A431 
membranes 
Membranes were prepared as in [9] but omitting 
Ca’+ and supplementing the buffer with EGTA to 
0.2 mM. Binding assays were performed in 0.2 ml 
of 75 mM Tris, 25 mM MgC12 (pH 7.4) containing 
varying amounts of radioligands and 50 pg mem- 
brane protein. After 25 min incubation at 30°C the 
reaction was stopped by addition of 1 ml ice-cold 
buffer and the samples immediately filtered on 
GF/C glass fibre filters (Whatman). Filters were 
washed 4 times with 4 ml ice-cold buffer, transfer- 
red to scintillation vials and soaked in 1 ml of 1 N 
HCl before addition of the scintillation cocktail. 
Non-specific binding was assessed in the 
presence of 100 FM I-isoproterenol. 
2.4. Inhibition of the binding of dihydro- 
alprenolol and CGP-12,177 by ,8-adrenergic 
agonists and antagonists 
Stereospecificity was assessed by inhibition 
curves on both intact cells and membrane prepara- 
tions using the radioligand CGP-12,177. Assay 
conditions were the same as described for satura- 
tion binding. The Ki (inhibition constant) values of 
the compounds were calculated from the 50% in- 
hibitory concentrations as in [lo]. 
The subtype of the A431 P-receptors was assess- 
ed by inhibition of dihydroalprenolol binding on 
membrane preparations with the agonists l- 
isoproterenol, 1-epinephrine and 1-norepinephrine. 
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The Ki values of the agonists were calculated as 
described above. 
2.5. Adenylate cyclase assay 
Adenylate cyclase activity was assayed as in [ 111. 
The reaction medium contained 100 ,uM [32P]ATP, 
7 mM MgCL, 1 mM EDTA, 1 mM CAMP, 50 mM 
Tris-HCl (pH 7.4), an ATP-regenerating system 
(1.5 mg/ml creatine phosphokinase, 1 mg/ml 
phosphocreatine) and 40-50 pg membrane protein 
in a final volume of 80~1. The reaction was in- 
itiated by addition of the membrane preparation 
and incubation continued for 20 min at 30°C. 
3. RESULTS 
In a screening of various cell lines, the human 
epidermoid transformed cell line, A43 1, was found 
to bind large amounts of the radiolabelled p- 
adrenergic antagonist [3H]dihydroalprenolol. The 
binding was displaceable by excess unlabelled 
alprenolol (not shown). Since the liposolubility of 
most fl-adrenergic antagonists causes non-specific 
binding on hydrophobic surfaces, the specificity of 
the binding to intact A431 cells was verified by 
displacement with the hydrophilic agonist l- 
isoproterenol [12]. Due to the high non-specific 
binding (fig.l), the saturation binding could only 
be studied up to concentrations of 5 nM. Calcula- 
tion of the association parameters by Scatchard 
analysis [ 131 yielded an association constant (Ka) 
of 1.1 + 0.3 x lo9 M-’ for a single type of binding 
site at a density of 110000 +_ 18OOO/cell. 
Since quantitation of dihydroalprenolol binding 
was hampered by the high non-specific binding, 
the presence of &receptors on intact cells was con- 
firmed by using the hydrophilic antagonist 
CGP-12,177 [8]. This ligand bound to the intact 
cell with a Ka of 1.4 f 0.4 x lo9 M-i for a single 
type of binding site at a density of 34000 + 
6OOO/cell (fig. 1). 
The binding of both radiolabelled ,&adrenergic 
antagonists was confirmed on A431 membrane 
preparations. Scatchard analysis of the binding 
curves (fig.2) showed for both ligands 2.2 +_ 
0.2 pmol bound/mg membrane protein with a Ka 
for dihydroalprenolol of 1.5 + 0.3 x lo8 M-’ and 
for CGP-12,177 of 2.5 + 0.9 x 10’ M-l. 
The stereospecificity of ligand binding was 
assessed on intact cells and membranes by the in- 
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Fig. 1. Saturation binding curves of [3H]dihydroal- 
prenolol (left) and CGP-12,177 (right) on intact A431 
cells. (Upper plots) Total binding (M), non-specific 
binding (W-O) and specific binding (A--A) of the 
radioligands on A431 cells. Means and SD of 4 
independent experiments are given. (Lower plots) 
Scatchard analysis of the specific binding curves. 
hibition of CGP-12,177 binding with the 
stereoisomers of the antagonist propranolol and 
the agonist isoproterenol (table 1). On intact cells 
I-propranolol had a 150-fold higher affinity for the 
receptor than the d-isomer, while I-isoproterenol 
had a 30-fold higher affinity. The inhibition con- 
stants for I-propranolol and I-isoproterenol were 
somewhat lower on A431 membrane preparations 
but the stereospecificity of these two ligands was 
well conserved (table 1). 
Using [3H]dihydroalprenolo1 as radioligand on 
A431 membrane preparations, the affinity of 3 
agonists for the &receptor was assessed by means 
of a competition assay. Isoproterenol showed the 
highest affinity, followed by epinephrine and 
norepinephrine (table 2). 
The functional coupling of the ,&adrenoreceptor 
to its effector system was verified by studying the 
stimulation of adenylate cyclase by the agonist l- 
isoproterenol. As shown in table 3, I-isoproterenol 
increased CAMP production 2.5-times over basal 
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Fig.2. Saturation binding curves of [3H]dihydroal- 
prenolol (left) and CGP-12,177 (right) on A431 
membrane preparations. (Upper plots) Total binding 
(M), non-specific binding (o--o) and specific 
binding (ti) of the radioligands on 50 pg membrane 
protein samples. The means of 2 independent experi- 
ments are given. (Lower plots) Scatchard analysis of the 
specific binding curves. 
Table 1 
Stereospecificity of &adrenergic ligands for the receptor 
on A431 cells 
Ligand Ki (X 106) (M-r) 
I-Propranolol 
d-Propranolol 
I-Isoproterenol 
d-Isoproterenol 
Intact cells Membranes 
7600 910 
50 17 
5 3.8 
0.15 0.45 
Inhibition constants (Ki) were calculated from 
displacement curves, using 1.5 nM CGP-12,177 as 
radiomarker on intact cells and 2.5 nM on membrane 
preparations. Experimental procedures are described in 
section 2 
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Table 2 
Subclass typing of the @receptors of A431 cells 
Agonist Kr (X 106) (M-l) 
I-Isoproterenol 1.6 
I-Epinephrine 0.38 
1-Norepinephrine 0.053 
Inhibition constants (Ki) were calculated from 
displacement curves using 5 nM [3H]dihydroalprenolol 
as radioligand on membrane preparations of A431 
cells (50 gg protein). Experimental procedures are 
described in section 2 
Table 3 
Adenylate cyclase stimulation on A431 membrane 
preparations 
Treatment pmol cAMP/mg 
protein per min 
- 
+ 100 yM I-isoproterenol 
+ 100 PM GPP(NH)P 
+ IOOrM Gpp(NH)p and 
I-isoproterenol 
+ 10 mM NaF 
4.0 
10.0 
16.8 
28.0 
24.9 
CAMP levels were determined as described in section 2 
CAMP levels, demonstrating the coupling of 
agonist-occupied receptor sites with the adenylate 
cyclase system. Additivity of the effects of l- 
isoproterenol with that of the nucleotide analogue 
Gpp(NH)p could be shown to reach the levels of 
activities found by NaF stimulation. 
4. DISCUSSION 
Most of our knowledge on the properties of 
mammalian /3-adrenergic receptors has been gain- 
ed from studies on transformed mouse lym- 
phocytes (S49 lymphoma) [4] or rat glial Ceh (c6 
glioma) [5]. The low number of sites/cell and low 
yield of receptor sites/mg membrane protein un- 
fortunately limit the use of these cells for purifica- 
tion procedures or visualisation of the &receptor 
by fluorescence or immunochemical techniques. 
Recently, a human liver cell line carrying 20000 
receptors was described, a sufficient number of 
receptors for use in photobleach recovery studies 
using a fluorescent &antagonist [6]. To increase 
the diversity of homogeneous human cell lines 
available for the study of &receptors, a screening 
of transformed cells was initiated. Among these 
the A431 epidermoid cell line seemed best suited 
(see below). 
The yield of receptors per mg protein from the 
A431 cell membrane is equal to or even higher than 
that found for the commonly used material for @- 
receptor purification: the turkey erythrocyte [ 141. 
This yield, 2.2 pmol/mg membrane protein, was 
similar when tested with two different radiola- 
belled antagonists, [3H]dihydroalprenolo1 and 
CGP- 12,177 [8]. The binding sites showed associa- 
tion constants comparable to those found for other 
&receptors. The stereospecificity of both agonists 
and antagonists confirmed the characterisation of 
the binding sites as P-receptors, and the order of 
potency of the agonists - isoproterenol > epine- 
phrine > norepinephrine - identifies them as 
&-receptors [15]. Finally, the receptor was shown 
to modulate the adenylate cyclase stimulation 
upon binding of isoproterenol. The &-receptors of 
the A431 cell line may thus be exploited for future 
purification and reconstitution experiments imilar 
to those described for the &-receptor of frog 
erythrocytes or lung tissues [16]. 
Comparing the yield of EGF-receptor/mg mem- 
brane protein (16 pmol) with the number of EGF- 
receptors/cell (2.6 x 106) for the A431 cell [17], 
2.2 pmol ,&receptors/mg membrane protein would 
result from approx. 300000 receptors/cell. The 
number of receptors obtained by dihydroalpre- 
nolo1 binding on intact cells is one-third of this 
value, while the number of receptors obtained by 
CGP- 12,177 binding is one-ninth. The discrepancy 
between the predicted and observed values could 
be due to the presence on or in the A431 cell of 
receptors which cannot be reached by hydrophilic 
agents but become accessible on isolated mem- 
branes. When the hydrophilic agonist l-isoprotere- 
no1 was used for non-specific binding measure- 
ments, part of the alprenolol binding sites could 
not be accounted for. The more hydrophilic anta- 
gonist, CGP-12,177, appears even less capable 
than I-isoproterenol of reaching all the P-receptors 
of the cell. However, even the lowest density of 
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receptors detected by CGP-12,177 would permit 
the use of the A431 cells for visualisation ex- 
periments of the type performed on Chang liver 
cells with the fluorescent label NBD-alprenolol [6]. 
To summarise, the A431 cell may provide a new 
tool not only for purification, analysis and 
reconstitution experiments on a human &-recep- 
tor, but also for the visualisation of the receptors 
at the fluorescence microscopy and ultrastructural 
level. 
ACKNOWLEDGEMENTS 
We thank Dr G. Todaro for the kind hospitality 
with which he received one of us (J.H.) in his 
laboratory at the National Cancer Institute. We 
also thank Dr M. Waterfield and Dr P. Stroobant 
(Imperial Cancer Foundation, London) for the 
A431 membrane preparations used in this work. 
Dr J.G. Guillet, MS C. Meo and Mr R. Schwartz- 
mann are thanked for their help in preparing the 
manuscript. This work was supported by grants 
from CNRS, DGRST and INSERM. We are 
grateful to the Association pour le Developpement 
de la Recherche sur le Cancer, the Fonds de la 
Recherche Medicale Francaise and the Ligue Fran- 
caise contre le Cancer. 
REFERENCES 
111 
121 
[31 
141 
151 
bl 
171 
181 
[91 
101 
111 
121 
1131 
[I41 
u51 
iI61 
[I71 
Strosberg, A.D., Couraud, P.O., Durieu- 
Trautmann, O., Delavier-Klutchko, C. and Andre, 
C. (1982) Trends Pharmacol. Sci. 3, 281-285. 
Lefkowitz, R.J. and Hoffmann, B.A. (1981) Curr. 
Rev. Biomed. 1, 61-70. 
Minneman, K.P., Weiland, G.A. and Molinoff, 
P.B. (1980) Mol. Pharmacol. 17, l-7. 
Insel, P.A., Maguire, M.E., Gilman, A.G., 
Bourne, H.R., Coffino, P. and Melmon, K.C. 
(1976) Mol. Pharmacol. 12, 1062-1069. 
Terasaki, W.C. and Brooker, G. (1978) J. Biol. 
Chem. 253, 5418-5425. 
Henis, Y.I., Hekman, M., Elson, E.E. and 
Helmreich, J.M. (1982) Proc. Natl. Acad. Sci. 
USA 79, 2907-2911. 
Fabricant, R.N., De Larco, J.E. and Todaro, G. J. 
(1977) Proc. Natl. Acad. Sci. USA 74, 565-569. 
Staehelin, M., Simons, P., Jaeggi, K. and Wigger, 
N. (1983) J. Biol. Chem. 258, 3496-3502. 
Thorn, D., Powell, A.J., Lloyd, C.W. and Rees, 
D.A. (1977) Biochem. J. 168, 187-194. 
Chen, Y.C. and Prusoff, W.H. (1973) Biochem. 
Pharmacol. 22, 3099-3108. 
Couraud, P.O., Delavier-Klutchko, C., Durieu- 
Trautmann, 0. and Strosberg, A.D. (1981) Bio- 
them. Biophys. Res. Commun. 99, 1295-1302. 
Dax, E.M. and Portilla, J.S. (1982) Mol. 
Pharmacol. 22, 5-7. 
Scatchard, G. (1949) Ann. NY Acad. Sci. 51, 
660-672. 
Durieu-Trautmann, O., Delavier-Klutchko, C., 
Vauquelin, G. and Strosberg, A.D. (1980) J. 
Supramol. Struct. 13, 411-419. 
Lands, A.M., Luduena, F.P. and Bruzzo, H.T. 
(1967) Life Sci. 6, 2241-2249. 
Cerione, R.A., Strulovici, B., Benovic, J.L., 
Lefkowitz, R.J. and Caron, M.G. (1983) Nature 
306, 562-566. 
Carpenter, G., King, L. and Cohen, S. (1979) J. 
Biol. Chem. 254, 4884-4891. 
155 
